Technical Analysis for BCRX - BioCryst Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade B $8.51 2.65% 0.22
BCRX closed up 2.65 percent on Wednesday, March 22, 2017, on 41 percent of normal volume.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical BCRX trend table...

Date Alert Name Type % Chg
Mar 21 New 52 Week High Bullish 2.65%
Mar 21 Bearish Engulfing Bearish 2.65%
Mar 21 Stochastic Sell Signal Bearish 2.65%
Mar 21 Slingshot Bullish Bullish Swing Setup 2.65%
Mar 21 Reversal New Highs Setup Bullish Swing Setup 2.65%
Mar 20 New 52 Week High Bullish -7.50%
Mar 17 NR7 Range Contraction -3.84%
Mar 17 NR7-2 Range Contraction -3.84%
Mar 17 Slingshot Bullish Bullish Swing Setup -3.84%
Mar 17 180 Bullish Setup Bullish Swing Setup -3.84%

Older signals for BCRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.
Basic chart:

Profile
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops novel drugs that block key enzymes involved in the pathogenesis of diseases. The company integrates the disciplines of biology, crystallography, medicinal chemistry, and computer modeling to discover and develop small molecule pharmaceuticals through the structure-guided drug design process. Its product candidates include peramivir, an intravenous neuraminidase inhibitor, which is approved for seasonal influenza in Japan and Korea, as well as in Phase III clinical trials for acute influenza; ulodesine, an oral purine nucleoside phosphorylase inhibitor, which has completed Phase II clinical trials for the treatment of gout; and forodesine, an oral purine nucleoside phosphorylase inhibitor that is in Phase II clinical trials for oncology. The company’s product candidates also comprise BCX4161, a Phase I oral serine protease inhibitor for kallikrein hereditary angioedema; and BCX4430, a preclinical, RNA dependent-RNA polymerase inhibitor for treating Filoviruses. It has collaborative relationships with Mundipharma International Holdings Limited for the development and commercialization of forodesine; and Shionogi & Co., Ltd. and Green Cross Corporation for the development and commercialization of peramivir. Biocryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Is BCRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.25
52 Week Low 2.48
Average Volume 1,905,179
200-Day Moving Average 5.0448
50-Day Moving Average 6.7532
20-Day Moving Average 7.787
10-Day Moving Average 8.697
Average True Range 0.5918
ADX 21.98
+DI 26.77
-DI: 18.7
Chandelier Exit (Long, 3 ATRs) 7.4746
Chandelier Exit (Short, 3 ATRs) 5.9754
Upper Bollinger Band 10.1518
Lower Bollinger Band 5.4222
Percent B (%b) 0.65
Bandwidth 0.607371